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was 2.670.41 (948 lesions) versus 2.660.45 (500 lesions) , respectively in the BES and
EES arm (p0.60). At 12 months follow-up, the primary endpoint was 7.0% in the BES
arm vs 7.9% in the EES arm (p0.66). In the BES and EES arm, 1.6% vs 1.6% patients
suffered cardiac death (p1.0), 3.3% vs 3.6% MI (p0.83), 4.3% vs 4.4% TVR (p1.0),
and 2.5% vs 2.0 TLR (p0.80), respectively. Definite and probable stent thrombosis rate
was 0.8% in BES and 1.6% in EES (p0.45), despite similar DAPT regimens.
Conclusions: In an all-comer population, treatment of small vessels with the biodegrad-
able polymer Nobori DES showed similar outcomes compared to the everolimus eluting
Xience/Promus stent.
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Background: The newer generation drug eluting stents (DES) have shown advantages
over first generation DES, particularly relating to long term safety. However, comparative
data for contemporary DES are still insufficient. We aim to compare safety and efficacy
between Nobori DES, eluting Biolimus A9 from an abluminal biodegradable polymer
(BES) and Xience/Promus DES eluting everolimus from a permanent polymer (EES).
Methods: COMPARE II, a prospective, randomized (2:1), controlled, multi-centre study,
enrolled 2707 patients (1795 BES arm, 912 EES arm) with limited exclusion criteria. The
primary endpoint was a composite of safety (cardiac death, non fatal myocardial
infarction-MI) and efficacy (target vessel revascularization-TVR) at 1 year. Dual anti-
platelet therapy was 12 months for both arms. The primary hypothesis was non-inferiority
of BES vs EES. Data were independently monitored and adverse events were adjudicated
by an independent clinical event committee.
Results: No significant differences were detected for any of the baseline characteristics.
The patients (74% male) were63 years old, 22% had diabetes mellitus, 20% history of
MI, 18% and 6% respectively had prior PCI or CABG. In both groups 58% of patients
were treated for acute coronary syndrome (21% for STEMI). Lesions complexity was
similar (B2/C: 63%), 14% ostial, 6% bifurcated, 20% thrombosed. Lesions were longer in
EES (17.7mm vs. 16.4mm in BES, p0.02), while mean number of stents per lesions was
similar (1.40.8). The 1 year primary endpoint was 5.2% in BES arm vs 4.8% in EES
arm, confirming the hypothesis of non-inferiority hypothesis (p0.0001). There were no
significant differences in any of the secondary endpoints: 0.8% vs 0.8% patients suffered
cardiac death, 2.8% vs 2.5% had a MI, 2.9% vs 2.2% underwent TVR, and 2.7% vs 2.2%
TLR in the BES and EES arm respectively. Definite and probable stent thrombosis rate
was 0.8% in BES and 1.0% in EES.
Conclusions: In the largest prospective randomised all-comer trial, the Nobori BES is
non-inferior compared to the Xience/Promus EES. Primary and secondary endpoints in
this real-life population were not significantly different between both stent groups, with
similar, low cardiac death and ST rates.
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Background: Despite the marked efficacy of first generation drug-eluting stents (DES)
on reducing neointimal hyperplasia (NIH), restenosis, and the need for repeat target lesion
revascularization (TLR) compared to bare metal stents, concerns regarding deliverability,
efficacy, and long-term safety,led to the development of new DES technologies. The
BioMime™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a novel DES system
that incorporates an ultra-thin stent platform (0,0026 strut thickness), a biodegradable
polymer and sirolimus. We report the initial human evaluation of the BioMime™ stent for
the treatment of diseased coronary vessels.
Methods: The meriT-1 trial was a prospective, non-randomized, single-arm, single center
first-in-man evaluation of the safety, feasibility and performance of the novel BioMime™
SES for the treatment of coronary lesions. Lesion criteria were single de novo stenosis
50-99% located in native vessels 2.5-3.5mm in diameter and19mm in length. Left main
and bifurcation lesions, in-stent restenosis, thrombus and total occlusion were excluded.
Clinical follow-up (FU) at 1-8-12 and 24 months, and all patients were assigned to
8-month angiographic FU. Primary endpoint was in-stent late lumen loss (LLL) at 8
months. MACE (major adverse cardiac events) was defined as cardiac death, MI and
ischemia-driven TLR.
Results: A total of 30 patients/lesions. Mean age 49.9 years, 30% diabetics, and 43% had
previous MI. By angiographic analysis, baseline median lesion length, reference diameter
and % diameter stenosis: 15.51mm [12.74;20.27], 2.94mm [2.71;3.33], and 80.5 [67.0;
90.7], respectively. Overall, 30 stents implanted (1 stent/lesion). Angiographic success-
(residual stenosis20%	 final TIMI flow grade 3) and procedural success (angiographic
success without MACE in index hospitalization) were 100%. At 8 months FU (26/30),
in-stent LLL was 0.15mm [0.09;0.33]; with no binary restenosis. Clinical FU at 12
months (30/30) showed no MACE or stent thrombosis.
Conclusions: In this first-in-human evaluation the novel BioMime™ SES had excellent
performance with high procedural success and efficacy on inhibiting NIH at 8 months.
There were no MACE or stent thrombosis up to 1 year.
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Background: New generation drug eluting stents (DES) which release everolimus or
zotarolimus have been shown to be safe and effective, but these permanent polymer DESs
are related to potential risk because of inflammatory reaction and delayed healing. In this
point, biodegradable polymer biolimus-eluting stent (BES) could enhance clinical
outcomes. The purpose of this study was to compare 1 year clinical outcome of
everolimus-eluting stent (EES), zotarolimus-eluting stent (ZES) and BES in multivessel
disease or long lesion.
Methods: Of total 3089 patients in single tertiary hospital from Jan 2008 to May 2011,
604 patients who treated with DES in multivessel (2 vessels) or long lesion (28mm)
who presented with stable or unstable angina were enrolled. Major adverse cardiovascular
event (MACE) was defined as composite endpoints of death, myocardial infarction (MI)
and revascularization through 12 month.
Results: BES, EES and ZES were implanted in 149 (24.7%), 270 (44.7%) and 185
(30.6%) patients. Demographics, past history and medications were not different among
3 groups. Total number of stents was similar (BES 2.21.0, EES 2.31.2 and ZES
2.21.3, p0.755) but there were differences in stent diameter (BES 3.030.30, EES
3.110.36, ZES 2.990.41, p0.002) and stent length (BES 45.418.7, EES 52.027.1
and ZES 52.830.2, p0.017). 1 year MACE showed no significant differences among
groups (BES 26.3%, EES 44.7%, ZES 28.9%, p0.960). There were no differences in
death, MI and revascularization.
Conclusions: In multivessel or long lesion, biodegradable polymer and permanent
polymer DES showed similar clinical outcomes at 1 year. Long-term follow-up is
warranted to discriminate clinical safety and efficacy.
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Background: Treatment of long lesions (LL) remains a challenge in interventional
cardiology, with a high propensity to restenosis. Our aim was to evaluate the clinical
outcomes of the patients with LL treated with a Nobori biolimus eluting stent (BES)
versus patients treated with an everolimus eluting stent (EES) in a real world / all-comer
situation as an substudy of COMPARE II trial.
Methods: Within the prospective, randomized, multi center COMPARE II study, a total
of 627 patients with long lesions (20 mm) were treated, of which 403 were randomized
(2:1) to the Nobori BES and 224 to the Xience EES. The primary endpoint was the
composite of safety (cardiac death, non fatal myocardial infarction) and efficacy (target
vessel revascularization) at 12 months. Data was independently monitored and all adverse
events were adjudicated by an independent clinical event committee.
Results: Baseline demographics were very similar between the two study arms: no
differences were found in risk factors except for current smoking (31.1% in BES arm vs
23.2% in EES arm; p0.05). Lesions were complex (B2/C: 77.2% vs 75.3%), with a high
incidence of moderate to severe calcification (39.4% vs 39.3%), ostial location (13.0% vs
11.3%) and thrombus present (16.8% vs 13.9%). The mean lesion length (mm) was
24.6 12.3 in the BES arm versus 25.2 12.6 in the EES arm, treated with 1.67  0.90
vs 1.57  0.80 stents per lesion, respectively. At 12 months follow-up, the primary
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